Table 1.

Human glioma cell line neuroglial profile and HLA class I and II phenotypes

GliomaNeuroglial*Molecular phenotype
Class I
Class II
04-11-MGV, F18, 57w6, w713, 17, 522, 6
12-11-MGN, GF24, 3227, 64w2, w84, 72, 3
13-06-MGN, GF, V1, 244, 57Not testedNTNT
A172N, V1, 38, 42w7NTNT
D-54MGN, V1, 37, 8w7NTNT
D-645MGV2, 2335, 49w4, w71, 4, 535, 8
DBTRG05-MGV, F2, 6835, 38w12, w154, 14, 52, 535, 8
NR203V, F27, 60w7, w104, 15, 51, 536, 7
NR206GF, V262w104, 538
NR213GF, V244, 55w5, w94, 15, 51, 536, 7
LN18NT2, 95, w35Not testedw3NT
LN229NT335w4, w12?NTNT
LNZ308N, V, F2435, 51w4, 14NTNT
SF767N1, 328, 44w5, w7NTNT
SNB19N, V218w5NTNT
T98GN, V, F235, 39w4, w78, 12, 524, 7
U-87MGN, V, F244w5NTNT
U-118MGN, V, F24, 2939, 44w7, 16NTNT
U-251MGN, V218w4NTNT
U-373MGGF, V218w5NTNT
  • NOTE: The gliomas were typed by a PCR-based molecular approach. NT, not tested; w4, w12? indicates that we cannot rule out in the presence of w4 in the presence of w12. Molecular specificities done by high-resolution HLA PCR: 04-11-MG—A0101; B08(01,19N)*, B5701; Cw0602, Cw07(01,06,18); DPB1 0101, DPB0301; DRB1 0301, DRB1302; DRB3 0101, DRB0301; DQB1 0201, DQB0604. D-645MG—A02(05,14), A23(01,02); B35(01,42), B4901; Cw04(01,09N), Cw07(01,06,18); DRB10101, DRB0405, DRB40103; DQB10302, DQB0501. DBTRG05-MG—A02(01,04,09), A68(01,11N,23); B35(01,42), B3801; Cw12(03,04), Cw15(02,07); DRB10402, DRB14(01,39); DRB3, DRB4; DQB10302, DQB0503. NR203—A0201, B07(02,05,06), B40(01,33); Cw0304, Cw0702; DPB10401, DRB10408, DRB1501; DRB40103, DRB0101; DQB10301, DQB0602. NR206—A0201; B1501; Cw0304; DPB11301; DRB10405; DRB40105; DQB10303. NR213—A0201; B44(02,10N,27), B5501; Cw0303, Cw05(01,03); DPB1 0401, DPB1101; DRB1 0401, DRB1501; DRB4 0103, DRB5(0101); DQB1 0301, DQB0602. T98G—A0201; B3503, B3906; Cw04(01,09N), Cw0702; DPB1 0301, DPB0401; DRB1 0801, DRB1201; DRB3 0202; DQB1 0302, DQB1 0402.

  • * The gliomas were profiled for neuroglial markers: neurofilament 160 (N), glial fibrillary acidic protein (GF), Galactocerebroside (GC), vimentin (V), and fibronectin (F).